DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

ULTRAGENYX PHARMAC (NASDAQ: RARE)

62.59 -0.36 (-0.57%)

Quote as of


company name or ticker

Recent Quotes

RARE $62.59 -0.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $63.35
Previous Close $62.95
Daily Range $60.50 - $63.35
52-Week Range $32.02 - $65.42
Market Cap $2.2B
P/E Ratio -27.98
Dividend (Yield) $0.00 (0.0%)
Volume 96,560
Average Daily Volume 349,284
Current FY EPS -$2.21

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

News & Commentary Rss Feed

Why Ultragenyx Pharmaceutical Inc. Stock Slumped

Ultragenyx shares aren't looking so "ultra" today after the company announced its intention to sell shares of common stock. Find out what this means for investors.

Use Options For a Chance To Buy RARE at a 31% Discount

Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the T

Ultragenyx Pharmaceutical (RARE): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape

UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcr

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Discusses Q4 2014 Results - Earnings Call Transcript

CRT Capital Initiates Coverage On Ultragenyx Pharmaceutical

Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatem

Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatemia

Monday's ETF Movers: XBI, RYT

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteo

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog

See More RARE News...